ALK and non-small cell lung carcinoma: These patients are known to have a different profile than those with other genomic alterations (EGFR, ALK, ROS, HER2, etc.)Our cohort appears to be representative of patients with BRAF V600E-mutant advanced NSCLC with 71% smokers despite a slightly older age (70.1 years) and a slight majority of women (55%).